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Abstract
Background: Before our study, there were no data concerning complex evaluation of: plasma 
PCSK9 concentrations, transcript LDL receptor (LDLR), as well as the total amount of 
monocytes’ LDLR in acute coronary syndrome (ACS) patients. PCSK9 levels in a few cohort 
studies were found to correlate with the number of white blood cells (WBC) or platelets (PLT). 
The study aims to evaluate PCSK9-LDLR concentrations, as well as to find any association 
between PCSK9 and WBC or PLT.
Methods: The study group included 95 consecutive patients with acute myocardial infarc-
tion, in whom angiography/angioplasty of the culprit vessel was performed. The control group 
consisted of 10 healthy young volunteers. Thirty patients from the studied group were qualified 
for further percutaneous revascularization after 3 months. Laboratory tests were performed 
using commercially available kits. LDLR expression on monocyte surface was measured by 
flow cytometry, but the mRNA level for LDLR was established by real time polymerase chain 
reaction. The PCSK9 plasma concentration was measured by ELISA kits.
Results: Higher concentration of PCSK9 and amount of LDLR on monocytes surface were observed 
in patients with ACS compared with healthy young volunteers (number of LDLRs on monocytes 
[reaction units] 10.8 ± 9.6 vs. 41.8 ± 11.8, p < 0.001, PCSK9 [ng/mL] 295.4 ± 76.4 vs. 213 ± 63.2,  
p < 0.001). A similar relationship was observed after application of 3-month intensive lipid-
-lowering therapy in patients with ACS (n = 30, PCSK9 [ng/mL] 281.1 ± 59.5 vs. 358.5 ± 74.7,  
p < 0.001, LDLR transcript [reaction units] 0.6 ± 0.32 vs. 1.87 ± 0.24, p < 0.001, number 
of LDLRs on monocytes [reaction units] 5.9 ± 3.1 vs. 22.3 ± 3.8, p < 0.001). There were 
no significant differences in levels of PCSK9, LDLR between patients with ST-segment eleva-
tion myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction 
(NSTEMI). There was no relation of the PCSK9 with WBC as well as with PLT.
Conclusions: We observed significantly higher concentration of PCSK9, and significantly 
higher levels of mRNA LDLR transcript in patients with ACS compared with healthy young 
volunteers. A similar pattern was observed after 3 months of intensive statin therapy among 
patients with ACS. There were no differences in these parameters between patients with 
STEMI vs. NSTEMI. The results of the study require confirmation in a larger population of 
patients. (Cardiol J 2016; 23, 6: 604–609)
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Introduction
Cardiovascular diseases (CVD) are the lead-
ing cause of death worldwide. It is estimated that 
in 2008, 17.3 million people died from the CVD, 
representing 30% of all deaths (World Health 
Organization, 2011). Approximately 7.3 million 
among this group suffered from coronary artery 
disease (CAD). Atherosclerosis is responsible for 
95% cases of CAD [1]. We know so much about the 
etiology and risk factors of CAD that the concept of 
the atherosclerotic plaque formation as a result of 
activation of local inflammation (in the vessel wall) 
was proposed several years ago [2–4]. Recent data 
seem to confirm this hypothesis [5]. There are in 
fact several papers suggesting that atherosclerosis 
can be considered not a local but also a systemic 
inflammation in the course of increased bone mar-
row activation [5–7]. The exponent of this process 
is increased white blood cell (WBC) count during 
acute coronary syndrome (ACS), lasting up to 
several months after the ACS, what seems to be 
a poor prognostic factor. The indirect proof of the 
above could be i.e. increased C-reactive protein 
(CRP) levels [1, 5, 8–10].
According to classical risk factors of athero-
sclerosis, it turns out that still, the most effective 
prevention is the reduction of low-density lipopro-
tein (LDL) plasma concentration [10–12]. These 
molecules are responsible for carrying components 
of atherosclerotic plaque such as free cholesterol, its 
esters, and other fatty compounds [1]. Exaggerated 
LDL biosynthesis, its impaired uptake by disturbed 
cellular receptor, or too small number of LDL re-
ceptors (LDLR), are dangerous due to the fact that 
they increase the plasma LDL concentrations [1]. 
These situations are often caused by abnormalities 
of genes coding sequence of: the LDLR protein, 
apoB100 protein (ligand for LDLR), or discovered 
several years ago — proprotein convertase subtili-
sin/kexin type 9 (PCSK9) protein [13].
After reviewing their biological role, the quan-
titative and qualitative disturbances of LDLR, 
PCSK9, and apoB100 were associated with the se-
verity of atherosclerosis and inflammation in large 
number of population studies [14]. Additionally, in 
a few cohort studies PCSK9 levels were found to 
correlate with the number of white blood cells or 
platelets [15, 16].
It is surprising that the evaluation of PCSK9 
and LDLR was usually conducted separately, in the 
population of hypercholesterolemic subjects with 
stable CAD [14]. The evaluation of these proteins 
has not been studied yet in ACS population in hu-
mans. This led us to create a prospective project, 
where plasma concentrations of PCSK9, the real 
time LDLR transcript levels and the amount of the 
LDLR particles on the monocytes were measured 
in patients with ACS. An additional objective was 
to evaluate a possible link of PCSK9 concentrations 
with WBCs, as well as with platelet counts.
Methods
The study included 95 consecutive patients 
with ACS (ST-segment elevation myocardial in-
farction [STEMI] and non-ST-segment elevation 
myocardial infarction [NSTEMI]). The control 
group consisted of 10 healthy volunteers. ACS 
patients were subjected to routine clinical manage-
ment specified in the guidelines of the European 
Society of Cardiology. Therefore, patients had 
performed urgent coronary angiography and an-
gioplasty of the infarct related artery. Morphology 
of peripheral blood and full lipid profile, as well as 
evaluation of glucose, troponin, aminotransferases, 
electrolytes, creatinine, and urea concentrations 
were determined routinely for every patient during 
hospital admission. Furthermore, during coronary 
angiography, blood samples for analysis of PCSK9, 
as well as for LDLR were obtained. Thirty patients 
from the study group were qualified for further 
percutaneous revascularization after 3 months. 
During second hospitalization, the same panel of 
laboratory tests was carried out with a molecular 
assessment of PCSK9 and LDLR.
The control group consisted of 10 healthy, 
anonymous volunteers, who had blood samples 
obtained to assess only concentrations of PCSK9, 
total amount of monocytes surface LDLRs, and 
evaluation of monocytes mRNA LDLR expression. 
The study protocol was approved by the Local 
Bioethics Committee.
Inclusion criteria to the study was ACS sched-
uled for urgent coronary angiography.
Exclusion criteria was the suspected patient’s 
life long less than 3 months.
Only 13% of patients (in ACS group) received 
statins before ACS hospitalization, but in low or 
intermediate dose regimen. Every subject who 
presented with myocardial infarction received 
80 mg of atorvastatin during hospital stay, and 
atorvastatin therapy was continued from discharge 
till the follow-up visit in a reduced dose of 40 mg. 
There were no patients who received ezetimibe 
during follow-up. At discharge each patient had 
been recommended an optimal medical therapy 
(with additional comorbidities), including high dose 
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statin thrapy (atorvastatin 40 mg daily) according 
to European Society of Cardiology guidelines [13].
No healthy volunteers received hypolipemic 
treatment at baseline.
Laboratory tests
Laboratory tests were performed using com-
mercially available diagnostic kits. The serum 
creatinine concentration was determined according 
to Jaffe’s reaction using Roche Cobas C (Hitachi, 
Germany). Creatinine clearance and glomerular 
filtration rate were estimated using Cockroft-Gault 
formulas. Potassium and sodium concentrations 
were determined by potentiometry using the 
Cobas System 6000 (Roche Diagnostics, Ger-
many). Assessments of peripheral blood counts 
were performed using Sysmex XT2000i (USA). 
Concentration of urea, uric acid, total cholesterol, 
triglycerides and high-density lipoproteins (HDL) 
were quantified using enzymatic colorimetric 
method (Cobas C Roche/Hitachi, Germany) with 
specific reagents. The concentration of LDL was 
calculated using the Friedewald formula.
LDLR, PCSK9 analysis
Monocytes derived from blood were selected 
in flow cytometry (Cytomics FC500MPL, Beck-
mann Coulter) using Flow-Count (Beckmann 
Coulter) and then ‘positive isolation’ by anty-CD14. 
LDLR amount on monocyte surface was studied by 
flow cytometry (Cytomics FC500MPL, Beckmann 
Coulter) using average fluorescence of antibodies 
against LDLR. RNA isolated from recruited mono-
cytes (in flow cytometry) was used to receive cDNA 
in reverse transcription-polymerase chain reaction 
(PCR). Then, synthetized cDNA was used to estab-
lish mRNA transcript level for LDLR by real time 
PCR with the usage of sophisticated starters. The 
starters were designed with OLIGO 6.65 software 
(Rychlik&Rhoads 1989-2002) based on LDLR gene 
sequence (ENSG00000130164) and Porphobilino-
gen deaminase sequence (ENSG00000256269) 
derived from Ensemble Gene View. The starters 
were prepared by Tib Molbiol.
The PCSK9 plasma concentration was meas-
ured by commercially available ELISA kits.
Statistical analysis
Normality was tested with the Shapiro-Wilk’s 
W test. At normal distribution of variables we used 
the Student’s t-test (for 2 independent and depend-
ent variables). Mann-Whitney test (for 2 independ-
ent variables) and Sign test, as well as the Wilcoxon 
matched pairs test (for 2 dependent variables) were 
used at abnormal variables of distribution. The 
results were given as mean ± standard deviation 
(SD). Statistical significance was set at p < 0.05. 
All analyzes were performed with STATISTICA 7.0 
(Statsoft, USA) and SPSS-20 (IBM, USA).
Results
The studied group included consecutive ACS 
patients with STEMI (n = 58), and NSTEMI (n = 37). 
The characteristics of the group are presented in 
Tables 1–3. All patients in the studied group had 
coronary-angiography performed. In 99% cases, 
percutaneous coronary intervention of the culprit 
vessel was conducted. NSTEMI patients did not 
significantly differ from STEMI subjects with 
respect to risk factors, clinical management and 
laboratory findings except for the levels of WBCs 
and blood glucose assessed at admission (NSTEMI 
vs. STEMI for WBC: 10.35 ± 3.7 vs. 12.5±3.9 µl/L; 
p = 0.006, for glucose: 7.38 ± 3.43 vs. 8.5 ± 3 mmol/L, 
p = 0.006, respectively).
The control group had blood taken only to 
assess: the PCSK9 concentrations, total amount 
of leucocytes surface LDLRs and monocytes 
LDLR transcript (mRNA) expression.
The value of PCSK9, LDLRs mRNA, and 
total monocytes LDLR amount (measured as 
an average fluorescence of anty-LDLR anti-
bodies) in ACS patients vs. healthy volunteers 
were as follows: PCSK9 295.4 ± 76.4 vs. 213 ± 
± 63.2 ng/mL, p < 0.001, number of LDLR tran-
script [reaction units] 1.8 ± 10.6 vs. 1.02 ± 0.1, 
p = NS, total leucocytes LDLR amount [reaction 
units] 10.8 ± 9.6 vs. 41.8 ± 11.8, p < 0.001 (Fig. 1).
The value of PCSK9, LDLRs mRNA, and 
total monocytes LDLR amount (measured as an 
average fluorescence of anti-LDLR antibodies) 
in STEMI patients vs. NSTEMI subjects were 
as follows: PCSK9 290.4 ± 74.4 vs. 303. 8 ± 
± 80.2 ng/mL, p = NS, number of LDLR transcript 
[reaction units] 2.5 ± 13.5 vs. 0.8 ± 0.22, p = NS, 
total leucocytes LDLR amount [reaction units] 
11 ± 10.3 vs. 10.4 ± 8.2, p = NS.
The value of PCSK9, LDLRs mRNA, and 
total monocytes LDLR amount (measured as 
an average fluorescence of anty-LDLR antibod-
ies) during ACS vs. 3 months after episode of 
myocardial infarction were as follows: n = 30, 
PCSK9 281.1 ± 59.5 vs. 358.5 ± 74.7 ng/mL, 
p < 0.001, number of LDLR transcript [reaction 
units] 0.6 ± 0.32 vs. 1.87 ± 0.24, p < 0.001, total 
leucocytes LDLR amount [reaction units] 5.9 ± 
± 3.1 vs. 22.3 ± 3.8, p < 0.001 (Fig. 2).
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There were no significant differences in PCSK9 
concentration, level of LDLR mRNA transcript 
expression, and total monocytes surface LDLR 
amount between diabetic vs. non-diabetic subjects, 
those receiving vs. those not taking statin (prior to 
the episode of ACS), between people with strongly 
severe CAD (3-vessel disease) vs. less severe CAD 
(1-vessel disease), or between obese (body mass 
index [BMI] > 25 kg/m2) vs. non-obese (BMI < 
< 25 kg/m2). No significant associations of the 
mRNA for LDLR, and total leucocytes surface LDLR 
with any of the analyzed parameter were found. Only 
a weak correlation between the concentration of 
PCSK9 and urea levels was noticed (R = 0.3, p < 
< 0.05). The significant reduction of total choles-
terol, LDL, WBC, hemoglobin, and hematocrit levels 
wase observed after 3 months from ACS episode 
among patients qualified for further percutaneous 
coronary revascularization (n = 30) (Table 4).
Discussion
Our project is probably a unique one to rank 
the simultaneous expression of LDLR and PCSK9 
concentration levels in patients with ACS. In 
addition, it is one of few trials evaluating (after 
Table 1. Characteristics of the studied group.
Parameter Mean SD
Age [years] 66.5 11.7
Body mass index [kg/m2] 27.5 4.9
Hemoglobin [mmol/L] 8.9 0.96
Hematocrit [%] 38.4 12
Erythrocytes [106/µL] 4.6 0.5
Leucocytes [103/µL] 11.7 3.9
Platelets [103/µL] 252.1 78.4
Glucose [mmol/L] 8.1 3.2
Creatinine [mmol/L] 82.2 27.5
Urea [mmol/L] 6.2 3.9
Uric acid [mmol/L] 337.4 102.8
Troponin [ng/L] 199.4 345.2
ASPAT [U/L] 61 73
ALAT [U/L] 33.5 24.8
Creatine phosphokinase [U] 448.1 556.1
Creatine kinase MB [U] 65.9 101.8
Total cholesterol [mg/dL] 219.4 56
HDL [mg/dL] 52.2 14.1
Non-HDL [mg/dL] 167.2 55.11
LDL [mg/dL] 139.6 51.4
Triglycerides [mg/dL] 141 74
Na+  [mmol/L] 138.7 2.8
K+ [mmol/L] 4.2 0.49
ALAT — alanine aminotransferase; ASPAT — aspartate amino-
transferase; HDL — high density lipoproteins; K — potassium; 
LDL — low density lipoproteins; Na — sodium; SD — standard 
deviation
Table 2. Characteristics of the studied group.
Women 33.68%
Death 1.05%
Coronary artery disease 24.21%
MI history 23.16%
CABG 2.11%
Heart failure 2.11%
Aortic aneurysm 1.05%
PAD (atherosclerosis of leg arteries) 2.11%
PAD (carotid atherosclerosis) 1.05%
Ischemic stroke 5.26%
Diabetes 32.63%
Hypertension 56.84%
Overweight 64.20%
Obesity 27.16%
Prior statin use in ACS subjects 13.83%
Chronic renal insufficiency 5.26%
COPD 7.37%
ACS — acute coronary syndrome; CABG — coronary artery  
by-pass graft; COPD — chronic obstructive pulmonary disease;  
MI — myocardial infarction; PAD — peripheral artery disease
Table 3. Characteristics of patients qualified for 
further percutaneous revascularization (n = 30), 
3 months after episode of myocardial infarction 
(n = 30).
Parameter Mean SD
Hemoglobin [mmol/L] 8.8 1.1
Hematocrit [%] 28.2 2
Erythrocytes [106/µL] 4.7 0.6
Leucocytes [103/µL] 7.4 1.9
Platelets [103/µL] 239.4 78.4
Na+ [mmol/L] 139.4 2.5
K+ [mmol/L] 4.4 0.4
Glucose [mmol/L] 5.95 1.2
Creatinine [mmol/L] 77 14
ASPAT [U] 21.7 5.3
ALAT [U] 29. 8 12.8
Total cholesterol [mg/dL] 172.2 46
HDL [mg/dL] 56 14.8
Non-HDL [mg/dL] 116.5 43.2
LDL [mg/dL] 93.3 39.6
Triglycerides [mg/dL] 115.2 43
ALAT — alanine aminotransferase; ASPAT — aspartate amino-
transferase; HDL — high density lipoproteins; K — potassium; 
LDL — low density lipoproteins; Na — sodium; SD — standard 
deviation
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3 months) the effect of intensive lipid lowering 
therapy (initiated during ACS) on the expression 
of LDLR and PCSK9. We observed significantly 
higher concentration of PCSK9 and levels of mRNA 
LDLR transcripts among ACS patients compared 
to healthy volunteers. On the other hand, the total 
amount of monocytes LDLR (functional assess-
ment of receptor) were significantly higher in the 
group of healthy individuals. The results were not 
surprising and should be explained by the sever-
ity of atherosclerosis, as well as pathobiochemical 
effects due to myocardial infarction. We can only 
speculate that the expression of PCSK9 is higher in 
ACS due to enhanced expression of LDLR, which in 
turn results in the necessity of absorbing increased 
amount of cholesterol (progression and activation 
of atherosclerosis) [1]. It is not surprising that ACS 
patients generally have lower number of LDLR 
particles, which is due to two facts. Firstly, ACS 
group is at highest cardiovascular risk. Secondly, 
one should remember that the control group con-
sisted of young, healthy people, and as it is known, 
the metabolism of LDL is age-dependent.
There were no differences in the expression 
of LDLR and concentrations of PCSK9 between 
patients with different types of myocardial infarc-
tion (STEMI, NSTEMI), between people with 
severe CAD (3-vessel disease) vs. less severe CAD 
(1-vessel disease), between obese (BMI > 25) 
vs. non-obese (BMI < 25), and diabetic vs. non-
diabetic patients.
We observed significantly higher concentra-
tion of PCSK9, levels of mRNA LDLR transcripts 
and total amount of surface monocyte LDLRs after 
3 months of intensive statin therapy, which were par-
allel to significant reduction in total cholesterol, LDL 
Figure 2. Comparison of the same patients during acute 
coronary syndrome (ACS) vs. 3-month period of inten-
sive statin therapy (initiated during ACS) according to 
value of PCSK9, LDLRs mRNA, and total monocytes 
LDLR amount (measured as an average fluorescence of 
anti-LDLR antibodies (see text); *p < 0.05.
Figure 1. Comparison of acute coronary syndrome (ACS) 
vs. healthy volunteers according to value of PCSK9, 
LDLRs mRNA, and total monocytes LDLR amount 
(measured as an average fluorescence of anti-LDLR 
antibodies (see text); *p < 0.05.
Table 4. Significant differences among (the same 
patients) during acute coronary syndrome versus 
3-month period after episode of myocardial  
infarction (n = 30).
Parameter Mean ± SD P
Hemoglobin [mmol/L] 9.4 ± 0.6
0.024
Hemoglobin after 3 months 8.7 ± 1.1
Hematocrit [103/µL] 30 ± 0.2
0.04
Hematocrit after 3 months 28 ± 0.2
Leucocytes [103/µL] 10.9 ± 3.5
< 0.001
Leucocytes after 3 months 7.4 ± 1.9
TC [mg/dL] 219.4 ± 45.6
0.003
TC after 3 months 173 ± 47.3
Non-HDL [mg/dL] 165.9 ± 45
0.024
Non-HDL after 3 months 116.6 ± 44.6
LDL [mg/dL] 134.8 ± 39.2
< 0.001
LDL after 3 months 94 ± 40.7
HDL — high density lipoprotein; LDL — low density lipoprotein;  
SD — standard deviation
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and non-HDL fraction. This result can be explained 
by physiological reaction to a statin [1]. Firstly, ac-
cording to the reduction of endogenous cholesterol 
biosynthesis, plasma LDL concentration decreases, 
which results in overexpression of LDLR expres-
sion (upregulation) [17–20]. In turn, the greater 
expression of the LDLR, the greater its counter-
regulation is potentiated. Function of PCSK9 is to 
attach to LDLR, which results in changing the LDLR 
conformation and prevention of the LDLR release 
from the endosome (the LDLR recirculation is 
impaired) [20, 21].Therefore, increased expression 
of the protein PCSK9 occurs to diminish the over-
expression of LDLR, to establish the balance [21]. 
To summarize, our clinical observations are consist-
ent with the mentioned biochemical data regarding 
the regulation of metabolism of LDL [18–20]. This 
effect was independent from statin dose, because 
every subject during hospital stay received 80 mg of 
atorvastatin, and atorvastatin therapy was continued 
from discharge till the follow-up visit in reduced 
dose of 40 mg. Only 13% of patients received statins 
before ACS hospitalization in low or intermediate 
dose regimen.
There was no association of PCSK9 with the 
number of platelets and WBC, but the reduction of 
WBC at 3 months after the infarction was observed. 
This is definitely a beneficial observation, in the light 
of current knowledge, where the worse prognosis 
of ACS patients is strictly associated with severity 
of systemic inflammatory response (the exponent 
of the phenomenon is increased activation of the 
bone marrow, and massive leukocyte formation) [5].
The weakness of the project is a small studied 
group, which explains discrepancies with other au-
thors’ results concerning the association between 
PCSK9 and the number of WBC. Additionally, 
results of laboratory parameters among studied 
patients should be interpreted with caution due 
to the fact that clinical conditions of STEMI and 
NSTEMI are characterized by various dynamics 
of assessment (different time from “door to bal-
loon”). There were no available data concerning 
CRP levels during episode of ACS. We had it during 
second hospitalization and there was no associa-
tion between CRP, PCSK9, and LDLR cascade. We 
decided not to present these results due to the fact 
that the group was very small.
Conclusions
In conclusion, we observed significantly higher 
concentration of PCSK9, and significantly higher 
levels of mRNA LDLR transcript in patients with 
ACS compared with healthy young volunteers. 
A similar pattern was observed after 3 months of 
intensive statin therapy among patients with ACS. 
There were no differences in these parameters 
between patients with STEMI vs. NSTEMI. The 
results of the study require confirmation in a larger 
population of patients.
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